Evidence map›Paper›PMID 40818211›Full record

ArticleOral oncology2025

Immune stratification in HPV-negative HNSCC: prognostic significance and prediction of immunotherapy response.

Shuai Xu, Yangfan Lv, HaiTao He, Chao Han, Jian Zhou, Di Yang, Hui Dong, Yiwei Zhang, Yi Zhang, Tingting Zhao and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oral oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Redefining oropharyngeal cancer in the HPV era: integrating precision medicine and immunotherapeutic frontiers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Shuai XuInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing 400038, People's Republic of China; Department of Head and Neck Surgery, The Second Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, People's Republic of China.
Yangfan LvDepartment of Pathology, The Second Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, People's Republic of China.
HaiTao HeDepartment of Head and Neck Surgery, The Second Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, People's Republic of China.
Chao HanInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing 400038, People's Republic of China.
Jian ZhouInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing 400038, People's Republic of China.
Di YangInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing 400038, People's Republic of China.
Hui DongInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing 400038, People's Republic of China.
Yiwei ZhangInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing 400038, People's Republic of China.
Yi ZhangChongqing International Institute for Immunology, Chongqing 400030, People's Republic of China.
Tingting ZhaoChongqing International Institute for Immunology, Chongqing 400030, People's Republic of China.
Xiangmei ChenDepartment of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing, China.
Jingbo ZhangDepartment of Nephrology, The Second Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, People's Republic of China.
Yi TianInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing 400038, People's Republic of China. Electronic address: tianyi@tmmu.edu.cn.
Yuzhang WuInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing 400038, People's Republic of China; Chongqing International Institute for Immunology, Chongqing 400030, People's Republic of China. Electronic address: wuyuzhang@tmmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor immune microenvironment (TIME) played a crucial role in head and neck squamous cell carcinoma (HNSCC), significantly impacting disease progression and immunotherapy. To address these complexities, we analyzed gene expression profiles of 790 HNSCC tumors by combining data from The Cancer Genome Atlas (TCGA; n = 520) and the Gene Expression Omnibu database (GEO, n = 270). We identified five distinct TIME-based phenotypes, with the E class-characterized by tertiary lymphoid structures (TLS)-showing the highest survival rates and immunotherapy responses. To assess TLS prognostic value, we evaluated two cohorts of human papillomavirus (HPV) infection negative HNSCC: 247 surgical resection patients and 35 immunotherapy-treated patients with postoperative recurrence/metastasis. Additionally, we analyzed the GEO dataset (n = 102) comprising HNSCC patients with metastasis/recurrence who received PD-1/PD-L1 inhibitors, integrating clinical and transcriptomic data. Immune stratification systems integrating TIME composition and immune cell counts revealed that TLS-positive patients exhibited superior survival and enhanced immunotherapy responses in HPV-negative HNSCC. The two immune stratification systems exhibited greater accuracy and predictive power in estimating the overall survival of HPV-negative HNSCC patients compared to the use of TNM staging and tumor pathological stage. These findings provided a framework for establishing TLS-based personalized treatment in HPV-negative HNSCC, potentially enhancing disease surveillance, informing clinical practice, and improving patient prognosis.

Indexed as

Head and Neck NeoplasmsImmunotherapySquamous Cell Carcinoma of Head and NeckAgedFemaleHumansMaleMiddle AgedPrognosisTumor MicroenvironmentHead and neck squamous cell carcinomaImmune classificationImmunotherapyPrognostic biomarkerTertiary lymphoid structureTumor-immune microenvironment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.